The vaccine against Covid-19 developed by the University of Oxford in collaboration with IRBM in Pomezia (Rome) will now be tested on children and the elderly. Phase 1 of clinical trials had involved 1.000 adults under 55 years old. Now over 10.200 people of different age groups (56-69, over 70 and between 5-12 years) will be enrolled and the vaccine effects on the immune system will be evaluated. Good outcomes from tests on monkeys, which hopefully can be replicated on humans.
Article published on ilcaffe.tv – 23/05/2020
Read the original article on ilcaffe.tv